Statins and glycaemic control in individuals with diabetes: A systematic review and meta-analysis

Diabetologia

Volumn 57, Issue 12, 2014, Pages 2444-2452

  Erqou, Sebhat ^a   Lee, C Christine ^b   Adler, Amanda I ^c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Diabetes mellitus; Glycaemic control; HbA1c; Meta analysis; Statins; Systematic review

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; GLUCOSE BLOOD LEVEL;

ARTICLE; DIABETES MELLITUS; DIABETIC PATIENT; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); BLOOD; CHEMICALLY INDUCED;

BLOOD GLUCOSE; DIABETES MELLITUS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 84926626548     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3374-x     Document Type: Article

References (41)

1. Sarwar N, Gao P, Seshasai SR et al (2010) Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375: 2215-2222.
2. Kearney PM, Blackwell L, Collins R et al (2008) Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 37: 117-125.
3. Third Report of the National Cholesterol Education Program(NCEP) (2002) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106: 3143-3421.
4. Rocco MB (2012) Statins and diabetes risk: fact, fiction, and clinical implications. Cleve Clin J Med 79: 883-893.
5. Stone NJ, Robinson J, Lichtenstein AH et al (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of theAmerican College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129(25 Suppl. 2): S1-S45.
6. Sattar N, Preiss D, Murray HM et al (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375: 735-742.
7. Maki KC, Ridker PM, Brown WV, Grundy SM, Sattar N (2014) An assessment by the statin diabetes safety task force: 2014 update. J Clin Lipidol 8(3 Suppl.): S17-S29.
8. Preiss D, Seshasai SR, Welsh P et al (2011) Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305: 2556-2564.
9. Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM (2013) Risk of incident diabetes among patients treated with statins: population based study. BMJ 346: f2610.
10. Sasaki J, IwashitaM, Kono S (2006) Statins: beneficial or adverse for glucose metabolism. J Atheroscler Thromb 13: 123-129.
11. Takano T, Yamakawa T, Takahashi M, KimuraM, OkamuraA (2006) Influences of statins on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 13: 95-100.
12. Kei A, Liberopoulos E, Elisaf M (2013) Effect of hypolipidemic treatment on glycemic profile in patients with mixed dyslipidemia. World J Diabetes 4: 365-371.
13. Simsek S, Schalkwijk CG, Wolffenbuttel BH (2012) Effects of rosuvastatin and atorvastatin on glycaemic control in type 2 diabetes-the CORALL study. Diabet Med 29: 628-631.
14. Liu PY, Lin LY, Lin HJ et al (2013) Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study). PLOS ONE 8: e76298.
15. Chapman MJ, Orsoni A, Robillard P, Hounslow N, Sponseller CA, Giral P (2014) Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights fromthe CAPITAIN and PREVAIL-US studies. Curr Med Res Opin 30: 775-784.
16. Behounek BD, McGovern ME, Kassler-Taub KB, Markowitz JS, Bergman M (1994) A multinational study of the effects of low-dose pravastatin in patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia. PravastatinMultinational Study Group for Diabetes. Clin Cardiol 17: 558-562.
17. Yamakawa T, Takano T, Tanaka S, Kadonosono K, Terauchi Y (2008) Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 15: 269-275.
18. Gumprecht J, Gosho M, Budinski D, Hounslow N (2011) Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes ObesMetab 13: 1047-1055.
19. Holman RR, Paul S, Farmer A, Tucker L, Stratton IM, Neil HA (2009) Atorvastatin in factorial with omega-3 EE90 risk reduction in diabetes (AFORRD): a randomised controlled trial. Diabetologia 52: 50-59.
20. Neil HA, Ceglarek U, Thiery J, Paul S, Farmer A, Holman RR (2010) Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: a randomised placebo controlled factorial trial. Atherosclerosis 213: 512-517.
21. Freed MI, Ratner R, Marcovina SM et al (2002) Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 90: 947-952.
22. Konduracka E, Galicka-Latala D, Cieslik G et al (2008) Effect of atorvastatin on endothelial function and inflammation in longduration type 1 diabetic patients without coronary heart disease and arterial hypertension. Diabetes Obes Metab 10: 719-725.
23. Collins R, Armitage J, Parish S, Sleigh P, Peto R (2003) MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361: 2005-2016.
24. Knopp RH, d′Emden M, Smilde JG, Pocock SJ (2006) Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the atorvastatin study for prevention of coronary heart disease endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 29: 1478-1485.
25. Colhoun HM, Betteridge DJ, Durrington PN et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364: 685-696.
26. Tajima N, Kurata H, Nakaya N et al (2008) Pravastatin reduces the risk for cardiovascular disease in Japanese hypercholesterolemic patients with impaired fasting glucose or diabetes: diabetes subanalysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) study. Atherosclerosis 199: 455-462.
27. Diabetes Atorvastin Lipid Intervention Study Group (2001) The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 24: 1335-1341.
28. Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12.
29. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
30. Nordin G, Dybkaer R (2007) Recommendation for term and measurement unit for 'HbA1c'. Clin Chem Lab Med 45: 1081-1082.
31. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558.
32. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
33. Egger M, Davey SG, Schneider M, Minder C (1997) Bias in metaanalysis detected by a simple, graphical test. BMJ 315: 629-634.
34. Cholesterol Treatment Trialists (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380: 581-590.
35. Ray KK, Seshasai SR, Wijesuriya S et al (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373: 1765-1772.
36. Ridker PM, Danielson E, Fonseca FA et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195-2207.
37. Goldfine AB (2012) Statins: is it really time to reassess benefits and risks? N Engl J Med 366: 1752-1755.
38. Yada T, Nakata M, Shiraishi T, Kakei M (1999) Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol 126: 1205-1213.
39. Mabuchi H, Higashikata T, Kawashiri M et al (2005) Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. J Atheroscler Thromb 12: 111-119.
40. Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T (2006) Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 49: 1881-1892.
41. Hao M, Head WS, Gunawardana SC, Hasty AH, Piston DW (2007) Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic beta-cell dysfunction. Diabetes 56: 2328-2338.